EN DE

Synektik S.A. (SNT) Fair Value & Analysis

Healthcare · PL · Market cap 3.3B PLN (≈ $879M) · ISIN PLSNKTK00019

What is Synektik S.A. really worth?

SS Synektik S.A. SNT · WAR
Price331.40 PLN
Fair Value265.49 PLN
Upside−19.9%
Quality68/100

A solid business, but trading 25% above our fair value of 265.49 PLN.

As of Sep 6, 2026, the fair value of Synektik S.A. is 265.49 PLN per share against a price of 331.40 PLN, so the fair value sits 20% below the price. A model estimate blended from multiple valuation models, recalculated regularly.

Watch Synektik S.A. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Healthy Growth (revenue 5y +40.3 %/yr)
✓Solidly profitable · 16.1% net margin
✓Low debt · generates free cash flow
✓Ranks above peers (10/13)
✓Wide moat 79/100

Risks

!Evidence only medium, so the estimate is less certain
!The models disagree: range 175.74 PLN to 550.69 PLN
!Weak on valuation: 7 out of 100
Evidence: Medium Range 175.74 PLN – 550.69 PLN

Fair value as of: Sep 6, 2026

From 26 valuation models · updated today

Share price −11.3% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The model range is unusually wide (175.74 PLN to 550.69 PLN). The outcome hinges heavily on assumptions, so read the point estimate with caution.
  • Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

394.00 PLN 20.16 PLN Fair Value 265.49 PLN May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 6, 2026.

How to read this chart

60‑month range 20.16 PLN – 394.00 PLN · fair‑value band 175.74 PLN – 550.69 PLN · the 331.40 PLN price screens above the 265.49 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 6, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Synektik S.A. (SNT) currently trades at 331.40 PLN, while our model-based Fair Value estimate is 265.49 PLN, implying the stock looks roughly 24.8% overvalued today. The Quality Score stands at 68/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of 447.34 PLN per share, and 11 of the 26 models we run sit above the 331.40 PLN price. Bear case: the Economic Profit group reads lowest at 92.10 PLN, and 15 of the 26 models stay below the price. Evidence for this calculation is medium.

It earns a return on equity of 55.1%. The balance sheet holds a net cash position of 59.8M PLN. The stock trades on a trailing P/E of 18.4. Fundamentals as of Sep 6, 2026

Our scenario range runs from 175.74 PLN (bear case) to 550.69 PLN (bull case); at 331.40 PLN, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 91% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at −20%, SNT screens cheaper than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly 10.60 PLN per share, which is 4.0 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF 122.47 PLN 183.71 PLN 374.65 PLN 76
Growth DCF 115.56 PLN 200.57 PLN 366.95 PLN 75
EPV 156.75 PLN 180.09 PLN 200.22 PLN 74
All 26 models by family
DCF Models
FCF DCF 122.47 PLN 183.71 PLN 374.65 PLN 76
Owner Earnings 194.42 PLN 419.95 PLN 876.01 PLN 71
5Y Revenue Exit 174.19 PLN 315.57 PLN 613.17 PLN 69
5Y EBITDA Exit 205.95 PLN 379.78 PLN 721.48 PLN 71
5Y P/E Exit 188.45 PLN 431.00 PLN 765.11 PLN 67
10Y Revenue Exit 153.78 PLN 372.89 PLN 526.68 PLN 65
10Y EBITDA Exit 183.73 PLN 439.73 PLN 899.40 PLN 63
10Y P/E Exit 171.24 PLN 402.90 PLN 791.68 PLN 60
Earnings-Based
Graham-Dodd 82.06 PLN 572.28 PLN 803.11 PLN 63
Lynch FV 249.79 PLN 356.85 PLN 463.90 PLN 61
PEG = 1.0 249.79 PLN 356.85 PLN 463.90 PLN 57
EPV 156.75 PLN 180.09 PLN 200.22 PLN 74
Dividend Discount
Gordon GGM 72.46 PLN 144.38 PLN 218.63 PLN 67
DDM Multi-Stage 72.46 PLN 124.77 PLN 152.40 PLN 67
Multiples
P/E Multiple 199.12 PLN 265.49 PLN 331.86 PLN 63
P/S Multiple 153.86 PLN 205.15 PLN 256.44 PLN 58
P/B Multiple 88.46 PLN 117.94 PLN 147.43 PLN 55
EV/EBIT 248.14 PLN 327.85 PLN 407.57 PLN 66
EV/EBITDA 231.81 PLN 306.09 PLN 380.36 PLN 67
EV/Revenue 176.80 PLN 248.73 PLN 320.65 PLN 54
Asset-Based
NCAV (Graham) 13.10 PLN 17.56 PLN 26.21 PLN 54
Growth DCF
Growth DCF 115.56 PLN 200.57 PLN 366.95 PLN 75
Rev-Margin DCF 184.11 PLN 359.29 PLN 706.31 PLN 68
Economic Profit
Residual Income 74.34 PLN 92.10 PLN 526.08 PLN 64
ROIC Compounder 177.04 PLN 229.71 PLN 292.91 PLN 72
Growth Earnings
Growth-Adj P/E 313.14 PLN 447.34 PLN 581.54 PLN 67

Widest divergence: Growth Earnings (447.34 PLN) versus Asset-Based (17.56 PLN). Highest evidence: FCF DCF (76).

Notify me when SNT reaches fair value

Put SNT on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 18.4
P/S ratio 2.77 P/E × margin
EPS (TTM) 18.04 PLN price ÷ EPS = P/E 18.4
Dividend yield 3.0% payout 54.5%
Net margin 15.1% FY2025
Return on equity 55.1% TTM
More key figures
Profitability
Return on assets (EBIT) 18.8% avg 5y
Operating margin 19.7% TTM
Growth
Revenue growth (YoY) +659% 3y avg +59.9%
EPS growth (YoY) +23.9%
Balance sheet & cash flow
Free cash flow 60.9M PLN FY2025
Net cash 59.8M PLN FY2024

Figures from reported company fundamentals · as of Sep 6, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 68/100

Of which business quality 68 · Market factors (momentum, volatility) 79

Profitability 91
Margins and returns on capital today
Quality Growth 56
Are margins and returns improving?
Cashflow 46
Earnings quality: real cash, not paper profit
Fin. Strength 84
Balance sheet, leverage, solvency risk
Investment 32
Disciplined investing over empire-building
Low Volatility 83
Calm price path (market factor)
Momentum 76
Price trend over the last 3–12 months (market factor)
52W Momentum 79
Distance to the 52-week high (market factor)
Net Issuance 82
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Synektik Spólka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. The company sells medical equipment used in diagnostics and therapy, and nuclear medicine.

Full company description

Synektik Spólka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. The company sells medical equipment used in diagnostics and therapy, and nuclear medicine. It is also involved in development of IT solutions used in radiology, as well as research, produces, and sells radiopharmaceutical products used in diagnostics for oncology. In addition, the company operates a research laboratory for diagnostic imaging systems and a service center for medical equipment. Further, it offers maintenance services for medical equipment, as well as acceptance and specialist tests. The company was founded in 2001 and is based in Warsaw, Poland.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Synektik S.A. reported revenue of 682M PLN in FY2025 versus 129M PLN in FY2021, a compound +51.7%/yr. Reported net income was 103M PLN in FY2025, compounding +87.2%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.

Growth Quality 100/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Latest Revenue (FY 2025)
682M PLN
Latest YoY
+9.2%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+59.9%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+40.3%
Avg. revenue growth/yr (15Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+22.9%
Value creation/yr (5Y) ⓘEarnings growth per share (CAGR 5 years) plus dividend yield: value created per share and year.
≈ +66.5% (approximate, leans on 2025) · in PLN
Earnings growth per share plus dividend yield: the value created per share and year.
Earnings growth per share+63.5%
Dividend yield3.0%
Trend ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.5Y 63.5% vs 10Y 48.3%, picking up
Operating margin (EBIT) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9.6% (2020) → 23.5% (2025) · rising
Worst earnings drop163% (2012) (loss year, drop beyond 100%) · in PLN
⚠ Rate leans on 2025: that final year sits 96% above its own trend (e.g. a one-off disposal gain) and could not be adjusted
Revenue +51.7%/yr
FY21 129M PLN
FY22 167M PLN
FY23 447M PLN
FY24 624M PLN
FY25 682M PLN
Net income +87.2%/yr
FY21 8.4M PLN
FY22 10.3M PLN
FY23 52.5M PLN
FY24 84.6M PLN
FY25 103M PLN
Character of growth · EPS growth decomposed (2013-2024) +23.4 % p.a.
Revenue per share +17.7 %

of which total revenue +19.2 % · buybacks/dilution −1.2 %

EBIT margin +3.6 %
Tax rate +0.0 %
Residual (interest, one-offs) +1.2 %

Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).

SNT screens 25% overvalued. Compare with Abbott Laboratories, →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Synektik S.A. · Fair Value
265.49 PLN −25%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Synektik S.A. Fair Value". https://www.fairvalue-calculator.com/stock/SNT.WAR

Peer Group

Medical Devices · 352 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 68 · Top 25%
Fair Value upside −20% · Above median
Return on equity (TTM) 55% · Top 25%
Return on assets 19% · Top 25%
Net margin (TTM) 16% · Top 25%
Operating margin (TTM) 20% · Top 25%
Revenue growth 659% · Top 25%
Dividend yield (TTM) 3.0% · Above median
Debt / equity 0.03× · Lower than median

Valuation Multiples vs Medical Devices median · lower = cheaper

P/E (TTM) 18.4× · Cheaper than median
P/B 3.94× · Pricier than 75% of peers
P/S (TTM) 16.22× · Pricier than 75% of peers
P/FCF 14.5× · Pricier than median

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE7 · sector 0
FUTURE100 · sector 32
PAST100 · sector 5
HEALTH98 · sector 97
DIVIDEND59 · sector 35

Insider activity: 40/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Sep 6, 2026).

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $112.47 $74.79 −34%
Stryker Corporation SYK $322.12 $186.28 −42%
Medtronic plc MDT $89.97 $65.57 −27%
Boston Scientific Corporation BSX $46.84 $30.73 −34%
Edwards Lifesciences Corporation EW $89.78 $41.02 −54%
Siemens Healthineers AG SHL €39.52 €33.87 −14%
DexCom, Inc DXCM $90.82 $38.95 −57%
GE HealthCare Technologies Inc GEHC $74.82 $64.13 −14%
Koninklijke Philips N.V PHIA €23.69 €14.36 −39%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥150.63 ¥147.63 −2%

Compare Synektik S.A. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is Synektik S.A. (SNT) overvalued or undervalued?
As of Sep 6, 2026, our model estimates a fair value of 265.49 PLN versus a price of 331.40 PLN, about −20% upside (overvalued).
What is the fair value of SNT?
Our model-based fair value for Synektik S.A. is 265.49 PLN (as of Sep 6, 2026), built from audited fundamentals. The current price: 331.40 PLN.
What is the quality score of SNT?
Synektik S.A. has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Synektik S.A. (SNT)?
Our model-based price target is the fair value of 265.49 PLN (as of Sep 6, 2026) from 26 valuation models. Cautious scenario 175.74 PLN, optimistic scenario 550.69 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Synektik S.A. stock forecast for 2026?
Our models put fair value at 265.49 PLN, about −20% upside versus a price of 331.40 PLN (overvalued). Cautious scenario 175.74 PLN, optimistic scenario 550.69 PLN. The calculation is refreshed regularly with new filings.
What is the net profit margin of SNT?
The net profit margin of Synektik S.A. is about 16.1%, meaning it keeps roughly 16.1% of revenue as net income. Based on the latest reported figures.
Does Synektik S.A. pay a dividend?
Synektik S.A. currently shows a dividend yield of about 2.97% relative to its recent price (as of Sep 6, 2026).
Free · no account needed

Watch Synektik S.A. in the live analysis

One click puts Synektik S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.